巨细胞动脉炎和风湿性多肌痛患者对SARS-CoV-2疫苗的体液和细胞免疫应答
本研究纳入45例巨细胞动脉炎(GCA)和33例风湿性多肌痛(PMR)患者,在疫苗接种前和和第二剂后4周评估抗Spike抗体浓度、Spike特异性T细胞频率及安全性和疾病活动度。GCA/PMR患者抗体浓度与匹配对照(n=98)相比未降低,但甲氨蝶呤和>10 mg/天泼尼松龙使用与较低抗体浓度显著相关;67%患者存在细胞免疫证据,>10 mg/天泼尼松龙者细胞免疫降低。接种未导致显著副作用或疾病活动度变化,结论为疫苗安全且免疫原性与其他老年人相当,但使用甲氨蝶呤尤其>10 mg/天泼尼松龙者疫苗应答较低。
要点
- GCA/PMR患者接种SARS-CoV-2疫苗后抗体浓度与年龄、性别和疫苗匹配的对照相比未降低。
- 甲氨蝶呤和>10 mg/天泼尼松龙使用与GCA/PMR患者较低抗体浓度显著相关。
- 67%的GCA/PMR患者ELIspot检测存在细胞免疫证据,>10 mg/天泼尼松龙者细胞免疫降低。
核心结论
- SARS-CoV-2疫苗接种对GCA/PMR患者是安全的,免疫原性与其他老年人相当。
- 使用甲氨蝶呤和尤其>10 mg/天泼尼松龙的患者疫苗应答较低,可能面临更高的(甚至可能严重的)突破性SARS-CoV-2感染风险。
研究设计与样本
- 研究纳入45例GCA和33例PMR患者,在接种前和接种第二剂(BNT162b2或ChAdOx1疫苗)后4周两次就诊。
- 排除既往SARS-CoV-2感染患者,抗体浓度与年龄、性别和疫苗匹配的对照组(n=98)比较,并用IFN-γ ELIspot检测Spike特异性T细胞频率,记录副作用和疾病活动度。
主要发现
- GCA/PMR患者抗体浓度与对照组相比未降低。
- 线性回归分析显示甲氨蝶呤和>10 mg/天泼尼松龙使用与GCA/PMR患者较低抗体浓度显著相关。
- 67%的GCA/PMR患者ELIspot检测存在细胞免疫证据;>10 mg/天泼尼松龙者细胞免疫降低。
- 接种未导致显著副作用或疾病活动度变化。
关键数值与推荐
- GCA/PMR患者(n=45 GCA,n=33 PMR)抗体浓度与匹配对照(n=98)相比未降低。
- 甲氨蝶呤和>10 mg/天泼尼松龙使用与较低抗体浓度显著相关。
- 67%的GCA/PMR患者存在细胞免疫证据;>10 mg/天泼尼松龙者细胞免疫降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are overlapping autoinflammatory diseases affecting people over 50 years. The diseases are treated with immunosuppressive drugs such as prednisolone, methotrexate, leflunomide and tocilizumab. In this study, we assessed the immunogenicity and safety of SARS-CoV-2 vaccinations in these diseases (based on humoral and cellular immunity). METHODS: Patients (n=45 GCA, n=33 PMR) visited the outpatient clinic twice: pre-vaccination and 4 weeks after the second dose (BNT162b2 or ChAdOx1 vaccine). Patients with previous SARS-CoV-2 infection were excluded. In both pre-vaccination and post-vaccination samples, anti-Spike antibody concentrations were assessed and compared with age-, sex- and vaccine-matched control groups (n=98). In addition, the frequency of SARS-CoV-2 Spike-specific T-cells was assessed by IFN-γ ELIspot assay, and side effects and disease activity were recorded. RESULTS: GCA/PMR patients did not have reduced antibody concentrations compared with controls. However, linear regression analysis revealed a significant association of methotrexate and >10 mg/day prednisolone use with lower antibody concentrations in GCA/PMR patients. Evidence of cellular immunity, as assessed by ELIspot assay, was found in 67% of GCA/PMR patients. Patients using >10 mg/day prednisolone had reduced cellular immunity. Importantly, vaccination did not lead to significant side effects or changes in disease activity. CONCLUSIONS: SARS-CoV-2 vaccination was safe for GCA/PMR patients and immunogenicity was comparable to other older individuals. However, patients using methotrexate and particularly >10 mg/day prednisolone did show lower vaccine responses, which corroborates findings in other autoinflammatory patient populations. These patients may therefore be at higher risk of (potentially even severe) breakthrough SARS-CoV-2 infection.
引用
- van Sleen Y, van der Geest KSM, Reitsema RD, et al. Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica. RMD Open. 2022. PMID: 39552442. doi:10.1136/rmdopen-2022-002479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。